Navigation Links
Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
Date:8/19/2008

BURLINGAME, Calif., August 19 /PRNewswire-FirstCall/ -- Urigen Pharmaceuticals, Inc. (OTC Bulletin Board: URGP, http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, today announced the U.S. Patent and Trademark Office has issued the first patent for the use of URG101, an investigational, bladder instillation treatment for Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC). Patent number US 7,414,039 broadly covers the use of the URG101 product in the treatment of PBS/IC. The term of the patent extends into 2025.

"Not only does this patent establish protection for the use of URG101 in Painful Bladder Syndrome and Interstitial Cystitis; it also validates the excellent intellectual property guidance provided by Tom Jurgensen, JD of Catalyst Law and Stephen Reiter, PhD, JD of Foley & Lardner," stated William J. Garner, MD, President and CEO of Urigen. "We will continue to execute our intellectual property strategy to strengthen our proprietary position in the field of PBS/IC."

Urigen has announced positive results from a Phase 2 study of URG101. The study was a multi-center, double-blind, placebo-controlled, crossover trial. Findings from the study included:

-- Primary Endpoint -- Improvement in Average Daytime Pain (p=0.03).

-- Secondary Endpoints -- Improvement in Daytime Urgency (p=0.03) and Total Symptom Score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by PORIS (p=0.01).

About URG101

URG101 is a pharmaceutical treatment for Painful Bladder Syndrome/Interstitial Cystitis that is instilled into the bladder. URG101 works with lidocaine reducing the sensations of pain, urge and muscle spasms and heparin, a glycosaminoglycan, coating the bladder wall thus augmenting the natural heparinoids.

About Painful Bladder Syndrome/Interstitial Cystitis (PBS)

Painful Bladder Syndrome/Interstitial Cystitis is a recognized medical condition with increased frequency of diagnosis. PBS/IC is characterized by bladder pain, urinary urgency and nocturia where few IC treatments exist and no approved therapies are available for PBS. Today, there are an estimated 10.5 million women and men in North America who suffer from PBS/IC.

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets Painful Bladder Syndrome/Interstitial Cystitis, which affects approximately 10.5 million men and women in North America. URG301 targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.

Contact:

Urigen Pharmaceuticals, Inc.

Martin E. Shmagin

Chief Financial Officer

http://www.urigen.com


'/>"/>
SOURCE Urigen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WallSt.net Announces Upcoming Interview with CSO and COO of Urigen Pharmaceuticals
2. Dr. Lisa Zdinak Announces, CO2TouchTM Brazilian Carboxytherapy - New Technology for Non-Surgical Treatment of Stretch Marks, Cellulite and Dark Undereye Circles
3. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
4. Medco Announces Research Collaboration with FDA Focused on Personalized Medicine
5. AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results
6. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
7. Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer
8. Pregis Announces Second Quarter 2008 Financial Results
9. WuXi PharmaTech Announces Second Quarter 2008 Results
10. Assurant Announces Two Executive Appointments
11. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: